Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
JNJ
BuyPremium GrowerJohnson & Johnson · Healthcare · United States · $645.9B · Avg Vol: $1.7B/d
COMPANY DESCRIPTION
Johnson & Johnson is a diversified global healthcare giant focused on Pharmaceuticals and MedTech. It develops and sells prescription drugs and a wide array of medical devices used in surgery, orthopedics, and other specialties. The company benefits from unparalleled global scale, extensive R&D capabilities, a vast portfolio of leading products, and strong distribution networks, maintaining a market leader position in many healthcare segments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 80.0B | 85.2B | 88.8B | 94.2B | 5.6% | 97.9B | 101.1B | 108.8B | 7.5% |
| EPS | 6.86 | 14.60 | 5.84 | 11.13 | 17.5% | 8.63 | 11.40 | 12.70 | 6.8% |
| Shares | 2.6B | 2.4B | 2.4B | 2.4B | -7.9% | 2.4B | — | — | — |
| Debt | 39.6B | 29.3B | 36.6B | 47.9B | 6.5% | 49.0B | — | — | — |
| Equity | 76.8B | 68.8B | 71.5B | 81.5B | 2.0% | — | — | — | — |
| Op CF | 21.2B | 22.8B | 24.3B | 24.5B | 5.0% | 27.6B | — | — | — |
| Inv CF | -12.4B | 878.0M | -18.6B | -23.6B | — | — | — | — | — |
| Fin CF | -8.9B | -15.8B | -3.1B | -5.5B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JNJ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| JNJ | Johnson & Johnson(you) | $645.9B | 67 | Buy |
| MRK | Merck & Co., Inc. | $366.0B | 64 | Hold |
| AZN.L | AstraZeneca PLC | $251.3B | 68 | Buy |
| LLY | Eli Lilly and Company | $1.0T | 78 | Buy |
| NVS | Novartis AG | $292.3B | 76 | Buy |
| ABBV | AbbVie Inc. | $451.5B | 87 | Strong Buy |
| RO.SW | Roche Holding AG | $360.3B | 86 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 75 | Buy |
| AMGN | Amgen Inc. | $233.8B | 86 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 88 | Strong Buy |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.5%